1 of 5
FEATURED COMPANIES
- Biocon/Mylan
- Coherus Biosciences Inc.
- Sandoz
- MORE
Pegfilgrastim Biosimilars Global Market Opportunities and Strategies to 2030: COVID 19 Impact and Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global pegfilgrastim biosimilars market.
Reasons to Purchase
Where is the largest and fastest growing market for the pegfilgrastim biosimilars market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The global pegfilgrastim biosimilars market opportunities and strategies to 2030 report answers all these questions and many more.
The report covers the following chapters
Countries: China, Japan, India, Australia, Indonesia, South Korea, USA, Brazil, UK, Germany, France, Russia.
Regions: Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Reasons to Purchase
- Outperform competitors using accurate up to date demand-side dynamics information.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Identify growth segments for investment.
- Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
- Create regional and country strategies on the basis of local data and analysis.
- Stay abreast of the latest customer and market research findings
- Benchmark performance against key competitors.
- Develop strategies based on likely future developments.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Gain a global perspective on the development of the market.
Where is the largest and fastest growing market for the pegfilgrastim biosimilars market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The global pegfilgrastim biosimilars market opportunities and strategies to 2030 report answers all these questions and many more.
The report covers the following chapters
- Executive Summary - The executive summary section of the report gives a brief overview and summary of the report
- Report Structure - This section gives the structure of the report and the information covered in the various sections.
- Introduction - The introduction section of the report gives brief introduction about segmentation by geography and segmentation by target antigen and by application.
- Market Characteristics - The market characteristics section of the report defines and explains the pegfilgrastim biosimilars market. This chapter includes different services covered in the report and basic definitions.
- Trends and Strategies - This chapter describes the major trends shaping the global pegfilgrastim biosimilars market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
- COVID Impact Analysis - This section provides an insight on how the pandemic is impacting the pegfilgrastim biosimilars market.
- Global Market Size and Growth - This section contains the global historic (2015-2019) and forecast (2023F, 2025F, 2030F) market values, and drivers and restraints that support and restrain the growth of the market in the historic and forecast periods.
- Regional Analysis - This section contains the historic (2015-2019), forecast (2019-2023F, 2025F, 2030F) market value and growth and market share comparison by region.
- Market Segmentation - This section contains the market values (2015-2019, 2019-2023F, 2025F, 2030F) and analysis for segment by type in the market.
- Regional Market Size and Growth - This section contains the region’s market size (2019), historic and forecast (2015-2019, and 2023F, 2025F, 2030F) market values, and growth and market share comparison of major countries within the region. This report includes information on all the regions (Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa).
- Competitive Landscape - This section covers details on the competitive landscape of the global pegfilgrastim biosimilars market, estimated market shares and company profiles of the leading players.
- Key Mergers and Acquisitions - This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Market Opportunities and Strategies - This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
- Conclusions and Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for pegfilgrastim biosimilars companies in terms of product offerings, geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
- By Application: Chemotherapy Induced Neutropenia; Transplantation; Others
- By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Mail Order/ Online Pharmacies
Countries: China, Japan, India, Australia, Indonesia, South Korea, USA, Brazil, UK, Germany, France, Russia.
Regions: Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 5
FEATURED COMPANIES
- Biocon/Mylan
- Coherus Biosciences Inc.
- Sandoz
- MORE
1. Pegfilgrastim Biosimilars Market Executive Summary
2. Table of Contents
3. List of Figures
4. List of Tables
5. Report Structure
6. Introduction
6.1.1. Segmentation by Geography
6.1.2. Segmentation by Application
6.1.3. Segmentation by Distribution Channel
7. Pegfilgrastim Biosimilars Market Characteristics
7.1. Market Definition
7.2. Market Segmentation by Application
7.2.1. Chemotherapy Induced Neutropenia
7.2.2. Transplantation
7.2.3. Others
7.3. Market Segmentation by Distribution Channel
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Mail Order/Online Pharmacies
8. Pegfilgrastim Biosimilars Market Trends and Strategies
8.1. Revised FDA Regulations To Facilitate Biosimilar Drug Development
8.2. Robust Research & Development
8.3. Large Number of Strategic Partnerships
8.4. Growing Mergers and Acquisitions
9. Pegfilgrastim Biosimilars Market, COVID Impact Analysis
9.1. Impact of COVID-19 On Major Pegfilgrastim Biosimilar Market Player Biocon Biologics
10. Global Pegfilgrastim Biosimilars Market Size and Growth
10.1. Market Size
10.2. Historic Market Growth, 2015-2019, Value ($ Million)
10.2.1. Drivers of The Market 2015-2019
10.2.2. Restraints of The Market 2015-2019
10.3. Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
10.3.1. Drivers of The Market 2019-2023
10.3.2. Restraints On The Market 2019-2023
11. Global Pegfilgrastim Biosimilars Market Segmentation
11.1. Global Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
11.1.1. Chemotherapy induced neutropenia
11.1.2. Transplantation
11.1.3. Others
11.2. Global Pegfilgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
11.2.1. Hospital pharmacies
11.2.2. Retail pharmacies
11.2.3. Mail-Order pharmacies
12. Pegfilgrastim Biosimilars Market, Regional and Country Analysis
12.1. Global Pegfilgrastim Biosimilars Market, by Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
12.2. Global Pegfilgrastim Biosimilars Market, by Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13. Asia-Pacific Pegfilgrastim Biosimilars Market
13.1. Asia-Pacific Pegfilgrastim Biosimilars Market Overview
13.1.1. Region Information
13.1.2. Impact of COVID-19
13.1.3. Market Information
13.1.4. Background Information
13.1.5. Government Initiatives
13.1.6. Regulations
13.1.7. Regulatory Bodies
13.1.8. Major Associations
13.1.9. Taxes Levied
13.1.10. Corporate Tax Structure
13.1.11. Investments
13.1.12. Major Companies
13.2. Asia-Pacific Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
13.3. Asia-Pacific Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.4. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.5. Asia-Pacific Pegfilgrastim Biosimilars Market: Country Analysis
13.6. China Pegfilgrastim Biosimilars Market
13.7. China Pegfilgrastim Biosimilars Market Overview
13.7.1. Country Information
13.7.2. Impact of COVID-19
13.7.3. Market Information
13.7.4. Background Information
13.7.5. Government Initiatives
13.7.6. Regulations
13.7.7. Regulatory Bodies
13.7.8. Major Associations
13.7.9. Taxes Levied
13.7.10. Corporate Tax Structure
13.7.11. Major Companies
13.8. China Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.9. China Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.10. India Pegfilgrastim Biosimilars Market
13.11. India Pegfilgrastim Biosimilars Market Overview
13.11.1. Country Information
13.11.2. Impact of COVID-19
13.11.3. Market Information
13.11.4. Background Information
13.11.5. Government Initiatives
13.11.6. Regulations
13.11.7. Regulatory Bodies
13.11.8. Major Associations
13.11.9. Taxes Levied
13.11.10. Corporate Tax Structure
13.11.11. Investments
13.11.12. Major Companies
13.12. India Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.13. India Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.14. Japan Pegfilgrastim Biosimilars Market
13.15. Japan Pegfilgrastim Biosimilars Market Overview
13.15.1. Country Information
13.15.2. Impact of COVID-19
13.15.3. Market Information
13.15.4. Background Information
13.15.5. Government Initiatives
13.15.6. Regulations
13.15.7. Regulatory Bodies
13.15.8. Major Associations
13.15.9. Taxes Levied
13.15.10. Corporate Tax Structure
13.15.11. Major Companies
13.16. Japan Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.17. Japan Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.18. Australia Pegfilgrastim Biosimilars Market
13.19. Australia Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
13.20. Australia Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.21. Australia Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.22. Indonesia Pegfilgrastim Biosimilars Market
13.23. Indonesia Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.24. Indonesia Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.25. South Korea Pegfilgrastim Biosimilars Market
13.26. South Korea Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
13.27. South Korea Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.28. South Korea Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
14. Western Europe Pegfilgrastim Biosimilars Market
14.1. Western Europe Pegfilgrastim Biosimilars Market Overview
14.1.1. Region Information
14.1.2. COVID Impact
14.1.3. Market Information
14.1.4. Background Information
14.1.5. Government Initiatives
14.1.6. Regulations
14.1.7. Regulatory Bodies
14.1.8. Major Associations
14.1.9. Taxes levied
14.1.10. Corporate Tax Structure
14.1.11. Investments
14.1.12. Major Companies
14.2. Western Europe Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
14.3. Western Europe Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
14.4. Western Europe Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
14.5. Western Europe Pegfilgrastim Biosimilars Market: Country Analysis
14.6. UK Pegfilgrastim Biosimilars Market
14.7. UK Pegfilgrastim Biosimilars Market Overview
14.7.1. Country Information
14.7.2. COVID Impact
14.7.3. Market Information
14.7.4. Background Information
14.7.5. Government Initiatives
14.7.6. Regulations
14.7.7. Regulatory Bodies
14.7.8. Major Associations
14.7.9. Taxes levied
14.7.10. Corporate Tax Structure
14.7.11. Investments
14.7.12. Major Companies
14.8. UK Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
14.9. UK Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
14.10. UK Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
14.11. Germany Pegfilgrastim Biosimilars Market
14.12. Germany Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
14.13. Germany Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
14.14. Germany Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
14.15. France Pegfilgrastim Biosimilars Market
14.16. France Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
14.17. France Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
14.18. France Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
15. Eastern Europe Pegfilgrastim Biosimilars Market
15.1. Eastern Europe Pegfilgrastim Biosimilars Market Overview
15.1.1. Region Information
15.1.2. COVID Impact
15.1.3. Market Information
15.1.4. Background Information
15.1.5. Government Initiatives
15.1.6. Regulations
15.1.7. Regulatory Bodies
15.1.8. Major Associations
15.1.9. Taxes levied
15.1.10. Corporate Tax Structure
15.1.11. Investments
15.1.12. Major Companies
15.2. Eastern Europe Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
15.3. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
15.4. Eastern Europe Pegfilgrastim Biosimilars Market: Country Analysis
15.5. Russia Pegfilgrastim Biosimilars Market
15.6. Russia Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
15.7. Russia Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
16. North America Pegfilgrastim Biosimilars Market
16.1. North America Pegfilgrastim Biosimilars Market Overview
16.1.1. Region Information
16.1.2. Impact of COVID-19
16.1.3. Market Information
16.1.4. Background Information
16.1.5. Government Initiatives
16.1.6. Regulations
16.1.7. Regulatory Bodies
16.1.8. Major Associations
16.1.9. Taxes Levied
16.1.10. Corporate Tax Structure
16.1.11. Investments
16.1.12. Major Companies
16.2. North America Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
16.3. North America Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
16.4. North America Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
16.5. North America Pegfilgrastim Biosimilars Market: Country Analysis
16.6. USA Pegfilgrastim Biosimilars Market
16.7. USA Pegfilgrastim Biosimilars Market Overview
16.7.1. Country Information
16.7.2. Impact of COVID-19
16.7.3. Market Information
16.7.4. Background Information
16.7.5. Government Initiatives
16.7.6. Regulations
16.7.7. Regulatory Bodies
16.7.8. Major Associations
16.7.9. Taxes Levied
16.7.10. Corporate Tax Structure
16.7.11. Investments
16.7.12. Major Companies
16.8. USA Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
16.9. USA Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
16.10. USA Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
17. South America Pegfilgrastim Biosimilars Market
17.1. South America Pegfilgrastim Biosimilars Market Overview
17.1.1. Region Information
17.1.2. Impact of COVID-19
17.1.3. Market Information
17.1.4. Background Information
17.1.5. Government Initiatives
17.1.6. Regulations
17.1.7. Regulatory Bodies
17.1.8. Major Associations
17.1.9. Taxes Levied
17.1.10. Corporate Tax Structure
17.1.11. Major Companies
17.2. South America Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
17.3. South America Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
17.4. South America Pegfilgrastim Biosimilars Market: Country Analysis
17.5. Brazil Pegfilgrastim Biosimilars Market
17.6. Brazil Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
17.7. Brazil Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
18. Middle East Pegfilgrastim Biosimilars Market
18.1. Middle East Pegfilgrastim Biosimilars Market Overview
18.1.1. Region Information
18.1.2. COVID Impact
18.1.3. Market Information
18.1.4. Background Information
18.1.5. Government Initiatives
18.1.6. Regulations
18.1.7. Regulatory Bodies
18.1.8. Major Associations
18.1.9. Taxes levied
18.1.10. Corporate Tax Structure
18.1.11. Investments
18.1.12. Major Companies
18.2. Middle East Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
18.3. Middle East Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
19. Africa Pegfilgrastim Biosimilars Market
19.1. Africa Pegfilgrastim Biosimilars Market Overview
19.1.1. Region Information
19.1.2. Impact of COVID-19
19.1.3. Market Information
19.1.4. Background Information
19.1.5. Government Initiatives
19.1.6. Regulations
19.1.7. Regulatory Bodies
19.1.8. Major Associations
19.1.9. Taxes Levied
19.1.10. Corporate Tax Structure
19.1.11. Major Companies
19.2. Africa Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
19.3. Africa Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
20. Global Pegfilgrastim Biosimilars Market Competitive Landscape
20.1. Company Profiles
20.2. Coherus Biosciences Inc.
20.2.1. Company Overview
20.2.2. Products and Services
20.2.3. Business Strategy
20.2.4. Financial Overview
20.3. Biocon
20.3.1. Company Overview
20.3.2. Products and Services
20.3.3. Business Strategy
20.3.4. Financial Overview
20.4. Mylan
20.4.1. Company Overview
20.4.2. Products and Services
20.4.3. Business Strategy
20.4.4. Financial Overview
20.5. Sandoz (Novartis)
20.5.1. Company Overview
20.5.2. Products and Services
20.5.3. Business Strategy
20.5.4. Financial Overview
21. Key Mergers and Acquisitions in The Pegfilgrastim Biosimilars Market
21.1. Ligand Pharmaceuticals Acquired Pfenex
21.2. True North Acquired Stake in Biocon Biologics
21.3. Biocon Acquires Pfizer's R&D Facility To Boost Biosimilars Development
21.4. Kashiv Pharma Acquired Adello Biologics
21.5. Mundipharma International Limited Acquired Cinfa Biotech
21.6. Biocon Merged With Sandoz
21.7. Fresenius Kabi Acquired The Biosimilars Business of Merck KGaA
22. Pegfilgrastim Biosimilars Market Opportunities and Strategies
22.1. Global Pegfilgrastim Biosimilars Market in 2023 - Countries Offering Most New Opportunities
22.2. Global Pegfilgrastim Biosimilars Market in 2023 - Segments Offering Most New Opportunities
22.3. Global Pegfilgrastim Biosimilars Market in 2023 - Growth Strategies
22.3.1. Market Trend Based Strategies
22.3.2. Competitor Strategies
23. Pegfilgrastim Biosimilars Market, Conclusions and Recommendations
23.1. Conclusions
23.2. Recommendations
23.2.1. Product
23.2.2. Place
23.2.3. Price
23.2.4. Promotion
23.2.5. People
24. Appendix
24.1. Market Data Sources
24.2. Research Methodology
24.3. Currencies
24.4. Research Inquiries
24.5. About the Publisher
24.6. Copyright and Disclaimer
2. Table of Contents
3. List of Figures
4. List of Tables
5. Report Structure
6. Introduction
6.1.1. Segmentation by Geography
6.1.2. Segmentation by Application
6.1.3. Segmentation by Distribution Channel
7. Pegfilgrastim Biosimilars Market Characteristics
7.1. Market Definition
7.2. Market Segmentation by Application
7.2.1. Chemotherapy Induced Neutropenia
7.2.2. Transplantation
7.2.3. Others
7.3. Market Segmentation by Distribution Channel
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Mail Order/Online Pharmacies
8. Pegfilgrastim Biosimilars Market Trends and Strategies
8.1. Revised FDA Regulations To Facilitate Biosimilar Drug Development
8.2. Robust Research & Development
8.3. Large Number of Strategic Partnerships
8.4. Growing Mergers and Acquisitions
9. Pegfilgrastim Biosimilars Market, COVID Impact Analysis
9.1. Impact of COVID-19 On Major Pegfilgrastim Biosimilar Market Player Biocon Biologics
10. Global Pegfilgrastim Biosimilars Market Size and Growth
10.1. Market Size
10.2. Historic Market Growth, 2015-2019, Value ($ Million)
10.2.1. Drivers of The Market 2015-2019
10.2.2. Restraints of The Market 2015-2019
10.3. Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
10.3.1. Drivers of The Market 2019-2023
10.3.2. Restraints On The Market 2019-2023
11. Global Pegfilgrastim Biosimilars Market Segmentation
11.1. Global Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
11.1.1. Chemotherapy induced neutropenia
11.1.2. Transplantation
11.1.3. Others
11.2. Global Pegfilgrastim Biosimilars Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
11.2.1. Hospital pharmacies
11.2.2. Retail pharmacies
11.2.3. Mail-Order pharmacies
12. Pegfilgrastim Biosimilars Market, Regional and Country Analysis
12.1. Global Pegfilgrastim Biosimilars Market, by Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
12.2. Global Pegfilgrastim Biosimilars Market, by Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13. Asia-Pacific Pegfilgrastim Biosimilars Market
13.1. Asia-Pacific Pegfilgrastim Biosimilars Market Overview
13.1.1. Region Information
13.1.2. Impact of COVID-19
13.1.3. Market Information
13.1.4. Background Information
13.1.5. Government Initiatives
13.1.6. Regulations
13.1.7. Regulatory Bodies
13.1.8. Major Associations
13.1.9. Taxes Levied
13.1.10. Corporate Tax Structure
13.1.11. Investments
13.1.12. Major Companies
13.2. Asia-Pacific Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
13.3. Asia-Pacific Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.4. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.5. Asia-Pacific Pegfilgrastim Biosimilars Market: Country Analysis
13.6. China Pegfilgrastim Biosimilars Market
13.7. China Pegfilgrastim Biosimilars Market Overview
13.7.1. Country Information
13.7.2. Impact of COVID-19
13.7.3. Market Information
13.7.4. Background Information
13.7.5. Government Initiatives
13.7.6. Regulations
13.7.7. Regulatory Bodies
13.7.8. Major Associations
13.7.9. Taxes Levied
13.7.10. Corporate Tax Structure
13.7.11. Major Companies
13.8. China Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.9. China Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.10. India Pegfilgrastim Biosimilars Market
13.11. India Pegfilgrastim Biosimilars Market Overview
13.11.1. Country Information
13.11.2. Impact of COVID-19
13.11.3. Market Information
13.11.4. Background Information
13.11.5. Government Initiatives
13.11.6. Regulations
13.11.7. Regulatory Bodies
13.11.8. Major Associations
13.11.9. Taxes Levied
13.11.10. Corporate Tax Structure
13.11.11. Investments
13.11.12. Major Companies
13.12. India Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.13. India Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.14. Japan Pegfilgrastim Biosimilars Market
13.15. Japan Pegfilgrastim Biosimilars Market Overview
13.15.1. Country Information
13.15.2. Impact of COVID-19
13.15.3. Market Information
13.15.4. Background Information
13.15.5. Government Initiatives
13.15.6. Regulations
13.15.7. Regulatory Bodies
13.15.8. Major Associations
13.15.9. Taxes Levied
13.15.10. Corporate Tax Structure
13.15.11. Major Companies
13.16. Japan Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.17. Japan Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.18. Australia Pegfilgrastim Biosimilars Market
13.19. Australia Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
13.20. Australia Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.21. Australia Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.22. Indonesia Pegfilgrastim Biosimilars Market
13.23. Indonesia Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.24. Indonesia Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
13.25. South Korea Pegfilgrastim Biosimilars Market
13.26. South Korea Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
13.27. South Korea Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
13.28. South Korea Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
14. Western Europe Pegfilgrastim Biosimilars Market
14.1. Western Europe Pegfilgrastim Biosimilars Market Overview
14.1.1. Region Information
14.1.2. COVID Impact
14.1.3. Market Information
14.1.4. Background Information
14.1.5. Government Initiatives
14.1.6. Regulations
14.1.7. Regulatory Bodies
14.1.8. Major Associations
14.1.9. Taxes levied
14.1.10. Corporate Tax Structure
14.1.11. Investments
14.1.12. Major Companies
14.2. Western Europe Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
14.3. Western Europe Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
14.4. Western Europe Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
14.5. Western Europe Pegfilgrastim Biosimilars Market: Country Analysis
14.6. UK Pegfilgrastim Biosimilars Market
14.7. UK Pegfilgrastim Biosimilars Market Overview
14.7.1. Country Information
14.7.2. COVID Impact
14.7.3. Market Information
14.7.4. Background Information
14.7.5. Government Initiatives
14.7.6. Regulations
14.7.7. Regulatory Bodies
14.7.8. Major Associations
14.7.9. Taxes levied
14.7.10. Corporate Tax Structure
14.7.11. Investments
14.7.12. Major Companies
14.8. UK Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
14.9. UK Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
14.10. UK Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
14.11. Germany Pegfilgrastim Biosimilars Market
14.12. Germany Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
14.13. Germany Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
14.14. Germany Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
14.15. France Pegfilgrastim Biosimilars Market
14.16. France Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
14.17. France Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
14.18. France Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
15. Eastern Europe Pegfilgrastim Biosimilars Market
15.1. Eastern Europe Pegfilgrastim Biosimilars Market Overview
15.1.1. Region Information
15.1.2. COVID Impact
15.1.3. Market Information
15.1.4. Background Information
15.1.5. Government Initiatives
15.1.6. Regulations
15.1.7. Regulatory Bodies
15.1.8. Major Associations
15.1.9. Taxes levied
15.1.10. Corporate Tax Structure
15.1.11. Investments
15.1.12. Major Companies
15.2. Eastern Europe Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
15.3. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
15.4. Eastern Europe Pegfilgrastim Biosimilars Market: Country Analysis
15.5. Russia Pegfilgrastim Biosimilars Market
15.6. Russia Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
15.7. Russia Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
16. North America Pegfilgrastim Biosimilars Market
16.1. North America Pegfilgrastim Biosimilars Market Overview
16.1.1. Region Information
16.1.2. Impact of COVID-19
16.1.3. Market Information
16.1.4. Background Information
16.1.5. Government Initiatives
16.1.6. Regulations
16.1.7. Regulatory Bodies
16.1.8. Major Associations
16.1.9. Taxes Levied
16.1.10. Corporate Tax Structure
16.1.11. Investments
16.1.12. Major Companies
16.2. North America Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
16.3. North America Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
16.4. North America Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
16.5. North America Pegfilgrastim Biosimilars Market: Country Analysis
16.6. USA Pegfilgrastim Biosimilars Market
16.7. USA Pegfilgrastim Biosimilars Market Overview
16.7.1. Country Information
16.7.2. Impact of COVID-19
16.7.3. Market Information
16.7.4. Background Information
16.7.5. Government Initiatives
16.7.6. Regulations
16.7.7. Regulatory Bodies
16.7.8. Major Associations
16.7.9. Taxes Levied
16.7.10. Corporate Tax Structure
16.7.11. Investments
16.7.12. Major Companies
16.8. USA Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015-2019, Value ($ Million)
16.9. USA Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
16.10. USA Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
17. South America Pegfilgrastim Biosimilars Market
17.1. South America Pegfilgrastim Biosimilars Market Overview
17.1.1. Region Information
17.1.2. Impact of COVID-19
17.1.3. Market Information
17.1.4. Background Information
17.1.5. Government Initiatives
17.1.6. Regulations
17.1.7. Regulatory Bodies
17.1.8. Major Associations
17.1.9. Taxes Levied
17.1.10. Corporate Tax Structure
17.1.11. Major Companies
17.2. South America Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
17.3. South America Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
17.4. South America Pegfilgrastim Biosimilars Market: Country Analysis
17.5. Brazil Pegfilgrastim Biosimilars Market
17.6. Brazil Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
17.7. Brazil Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
18. Middle East Pegfilgrastim Biosimilars Market
18.1. Middle East Pegfilgrastim Biosimilars Market Overview
18.1.1. Region Information
18.1.2. COVID Impact
18.1.3. Market Information
18.1.4. Background Information
18.1.5. Government Initiatives
18.1.6. Regulations
18.1.7. Regulatory Bodies
18.1.8. Major Associations
18.1.9. Taxes levied
18.1.10. Corporate Tax Structure
18.1.11. Investments
18.1.12. Major Companies
18.2. Middle East Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
18.3. Middle East Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
19. Africa Pegfilgrastim Biosimilars Market
19.1. Africa Pegfilgrastim Biosimilars Market Overview
19.1.1. Region Information
19.1.2. Impact of COVID-19
19.1.3. Market Information
19.1.4. Background Information
19.1.5. Government Initiatives
19.1.6. Regulations
19.1.7. Regulatory Bodies
19.1.8. Major Associations
19.1.9. Taxes Levied
19.1.10. Corporate Tax Structure
19.1.11. Major Companies
19.2. Africa Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019-2023, 2025F, 2030F Value ($ Million)
19.3. Africa Pegfilgrastim Biosimilars Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, Value ($ Million)
20. Global Pegfilgrastim Biosimilars Market Competitive Landscape
20.1. Company Profiles
20.2. Coherus Biosciences Inc.
20.2.1. Company Overview
20.2.2. Products and Services
20.2.3. Business Strategy
20.2.4. Financial Overview
20.3. Biocon
20.3.1. Company Overview
20.3.2. Products and Services
20.3.3. Business Strategy
20.3.4. Financial Overview
20.4. Mylan
20.4.1. Company Overview
20.4.2. Products and Services
20.4.3. Business Strategy
20.4.4. Financial Overview
20.5. Sandoz (Novartis)
20.5.1. Company Overview
20.5.2. Products and Services
20.5.3. Business Strategy
20.5.4. Financial Overview
21. Key Mergers and Acquisitions in The Pegfilgrastim Biosimilars Market
21.1. Ligand Pharmaceuticals Acquired Pfenex
21.2. True North Acquired Stake in Biocon Biologics
21.3. Biocon Acquires Pfizer's R&D Facility To Boost Biosimilars Development
21.4. Kashiv Pharma Acquired Adello Biologics
21.5. Mundipharma International Limited Acquired Cinfa Biotech
21.6. Biocon Merged With Sandoz
21.7. Fresenius Kabi Acquired The Biosimilars Business of Merck KGaA
22. Pegfilgrastim Biosimilars Market Opportunities and Strategies
22.1. Global Pegfilgrastim Biosimilars Market in 2023 - Countries Offering Most New Opportunities
22.2. Global Pegfilgrastim Biosimilars Market in 2023 - Segments Offering Most New Opportunities
22.3. Global Pegfilgrastim Biosimilars Market in 2023 - Growth Strategies
22.3.1. Market Trend Based Strategies
22.3.2. Competitor Strategies
23. Pegfilgrastim Biosimilars Market, Conclusions and Recommendations
23.1. Conclusions
23.2. Recommendations
23.2.1. Product
23.2.2. Place
23.2.3. Price
23.2.4. Promotion
23.2.5. People
24. Appendix
24.1. Market Data Sources
24.2. Research Methodology
24.3. Currencies
24.4. Research Inquiries
24.5. About the Publisher
24.6. Copyright and Disclaimer
Note: Product cover images may vary from those shown
3 of 5
FEATURED COMPANIES
- Biocon/Mylan
- Coherus Biosciences Inc.
- Sandoz
- MORE
The pegfilgrastim biosimilars market consist of sales of pegfilgrastim biosimilar drugs and related services. The drugs are used during the course of cancer treatment in order to reduce the infection risk for those patients undergoing immunosuppressant treatments, such as chemotherapy. The drug has further applications where protection from infections where immune system is compromised, such as in bone marrow transplants. It covers 2015 to 2019, termed the historic period, and 2019 to 2023 termed the forecast period, along with further forecasts for the periods 2023-2025 and 2025-2030.
The global pegfilgrastim biosimilars market reached a value of nearly $876.0 million in 2019. The market is expected to grow from $876.0 million in 2019 to $1,119.2million in 2023 at a rate of 6.3%. The growth is mainly due to an increased prevalence of cancer and increased adoption of the biosimilars. The market is expected to stabilize and reach $1,538.6 million in 2025 and $3,598.3 million in 2030.
Growth in the historic period resulted from government initiatives for biosimilars, increase in healthcare expenditure, and increase in pharmaceutical R&D expenditure and low costs of biosimilars. This growth was restricted by low rate of drug approvals, and lack of awareness on biosimilars among primary care physicians and specialists.
Going forward, aging population, increase in healthcare access and rising prevalence of chronic diseases are expected to drive the market. Effect of COVID-19, stringent regulations related to biosimilar approvals and prolonged production and approval time are major factors that could hinder the growth of the pegfilgrastim biosimilars market in the future.
The pegfilgrastim biosimilars market is segmented by application into chemotherapy induced neutropenia, transplantation and others. The chemotherapy induced neutropenia was the largest segment of the pegfilgrastim biosimilars market by application, accounting for 75.2% of the total market in 2019. Going forward, chemotherapy induced neutropenia segment is also expected to be the fastest growing segment in the pegfilgrastim biosimilar market, at a CAGR of 18.9%.
The pegfilgrastim biosimilars market is also segmented by distribution channel into hospital pharmacies, retail pharmacies and mail order/ online pharmacies. The hospital pharmacies was the largest segment of the pegfilgrastim biosimilars market by application, accounting for 89.8% of the total market in 2019. Going forward, the retail pharmacies segment is expected to be the fastest growing segment in the pegfilgrastim biosimilars market, at a CAGR of 30.4%.
North America was the largest region in the global pegfilgrastim biosimilars market, accounting for 51.1% of the total in 2019. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the pegfilgrastim biosimilars market will be Middle East and Asia Pacific, where growth will be at CAGRs of 34.8% and 30.3% respectively.
The pegfilgrastim biosimilars market is particularly prone to disruption from the coronavirus outbreak, as patients with cancer are more susceptible to viral infections, especially after chemotherapy, stem cell transplants, or surgeries thus preferring the biologic drug over the biosimilar.
The pegfilgrastim biosimilars market is concentrated, with a small number of large of large players in the market. Major players in the market include Coherus Biosciences Inc., Biocon/Mylan and Sandoz.
The top opportunities in the pegfilgrastim biosimilars market segmented by application will arise in the chemotherapy induced neutropenia segment, which will gain $194.2 million of global annual sales by 2023. The top opportunities in the pegfilgrastim biosimilars market segmented by distribution channel will arise in the hospital pharmacies segment, which will gain $127.6 million of global annual sales by 2023. The pegfilgrastim biosimilars market size will gain the most in the USA at $120.2 million.
Market-trend-based strategies for the pegfilgrastim biosimilars market include taking advantage of the less stringent regulations to develop new and improved biosimilars, investing extensively in R&D activities for the development of effective and innovative biologics, focusing on establishing strategic partnerships with the large players to expand their research and developments activities in new drug developments and increasing their focus on M&A growth strategies to expand the customer base and their geographic markets.. Player-adopted strategies in the pegfilgrastim biosimilars market include investing in expanding operations in different geographies, improving infrastructure and in acquisitions and mergers to strengthen their service offerings.
To take advantage of the opportunities, the publisher recommends the pegfilgrastim biosimilars companies to focus on strategic partnerships, focus on research & development, expand in emerging markets, leverage e-commerce to maximize reach and revenues, leverage online pharmacies, provide competitively priced offerings in low-income countries to reach new users, companies should focus on creating awareness, and focus on creating awareness among patients and doctors.
The global pegfilgrastim biosimilars market reached a value of nearly $876.0 million in 2019. The market is expected to grow from $876.0 million in 2019 to $1,119.2million in 2023 at a rate of 6.3%. The growth is mainly due to an increased prevalence of cancer and increased adoption of the biosimilars. The market is expected to stabilize and reach $1,538.6 million in 2025 and $3,598.3 million in 2030.
Growth in the historic period resulted from government initiatives for biosimilars, increase in healthcare expenditure, and increase in pharmaceutical R&D expenditure and low costs of biosimilars. This growth was restricted by low rate of drug approvals, and lack of awareness on biosimilars among primary care physicians and specialists.
Going forward, aging population, increase in healthcare access and rising prevalence of chronic diseases are expected to drive the market. Effect of COVID-19, stringent regulations related to biosimilar approvals and prolonged production and approval time are major factors that could hinder the growth of the pegfilgrastim biosimilars market in the future.
The pegfilgrastim biosimilars market is segmented by application into chemotherapy induced neutropenia, transplantation and others. The chemotherapy induced neutropenia was the largest segment of the pegfilgrastim biosimilars market by application, accounting for 75.2% of the total market in 2019. Going forward, chemotherapy induced neutropenia segment is also expected to be the fastest growing segment in the pegfilgrastim biosimilar market, at a CAGR of 18.9%.
The pegfilgrastim biosimilars market is also segmented by distribution channel into hospital pharmacies, retail pharmacies and mail order/ online pharmacies. The hospital pharmacies was the largest segment of the pegfilgrastim biosimilars market by application, accounting for 89.8% of the total market in 2019. Going forward, the retail pharmacies segment is expected to be the fastest growing segment in the pegfilgrastim biosimilars market, at a CAGR of 30.4%.
North America was the largest region in the global pegfilgrastim biosimilars market, accounting for 51.1% of the total in 2019. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the pegfilgrastim biosimilars market will be Middle East and Asia Pacific, where growth will be at CAGRs of 34.8% and 30.3% respectively.
The pegfilgrastim biosimilars market is particularly prone to disruption from the coronavirus outbreak, as patients with cancer are more susceptible to viral infections, especially after chemotherapy, stem cell transplants, or surgeries thus preferring the biologic drug over the biosimilar.
The pegfilgrastim biosimilars market is concentrated, with a small number of large of large players in the market. Major players in the market include Coherus Biosciences Inc., Biocon/Mylan and Sandoz.
The top opportunities in the pegfilgrastim biosimilars market segmented by application will arise in the chemotherapy induced neutropenia segment, which will gain $194.2 million of global annual sales by 2023. The top opportunities in the pegfilgrastim biosimilars market segmented by distribution channel will arise in the hospital pharmacies segment, which will gain $127.6 million of global annual sales by 2023. The pegfilgrastim biosimilars market size will gain the most in the USA at $120.2 million.
Market-trend-based strategies for the pegfilgrastim biosimilars market include taking advantage of the less stringent regulations to develop new and improved biosimilars, investing extensively in R&D activities for the development of effective and innovative biologics, focusing on establishing strategic partnerships with the large players to expand their research and developments activities in new drug developments and increasing their focus on M&A growth strategies to expand the customer base and their geographic markets.. Player-adopted strategies in the pegfilgrastim biosimilars market include investing in expanding operations in different geographies, improving infrastructure and in acquisitions and mergers to strengthen their service offerings.
To take advantage of the opportunities, the publisher recommends the pegfilgrastim biosimilars companies to focus on strategic partnerships, focus on research & development, expand in emerging markets, leverage e-commerce to maximize reach and revenues, leverage online pharmacies, provide competitively priced offerings in low-income countries to reach new users, companies should focus on creating awareness, and focus on creating awareness among patients and doctors.
Note: Product cover images may vary from those shown
4 of 5
- Coherus Biosciences Inc.
- Biocon/Mylan
- Sandoz
Note: Product cover images may vary from those shown
5 of 5
LOADING...
